公开(公告)号：US20170165289A1

公开(公告)日：2017-06-15

申请号：US15434318

申请日：2017-02-16

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Jihua Liu ,  Li Wang ,  Bharat Majeti ,  Roger Adami ,  Wenbin Ying

IPC: A61K31/713 ,  A61K9/51 ,  A61K31/7105

Abstract: This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

公开(公告)号：US09456984B2

公开(公告)日：2016-10-04

申请号：US14294021

申请日：2014-06-02

Applicant: NITTO DENKO CORPORATION

Inventor： Yoshiro Niitsu ,  Victor Knopov ,  Joseph E. Payne ,  Richard P. Witte ,  Mohammad Ahmadian ,  Loren A. Perelman ,  Violetta Akopian ,  Yasunobu Tanaka ,  Elena Feinstein ,  Sharon Avkin-Nahum ,  Hagar Kalinski ,  Igor Mett ,  Kenjiro Minomi ,  Wenbin Ying ,  Yun Liu

IPC: C12N15/11 ,  A61K9/127 ,  C12N15/113 ,  A61K31/713 ,  C07H21/02

CPC classification number: A61K9/1271 ,  A61K9/127 ,  A61K31/713 ,  C07H21/02 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2320/52

Abstract: What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Abstract translation: 描述的是通过施用包含脂质和类视色素的药物载体和包含与编码人hsp47的mRNA的反义序列的双链核酸分子的药物组合物来治疗纤维化疾病的方法。

公开(公告)号：US20160215286A1

公开(公告)日：2016-07-28

申请号：US14979577

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Akihiro Yoneda ,  Yasuyuki Tamura ,  Kenjirou Minomi ,  Bharat Majeti ,  Jihua Liu ,  Yun Liu ,  Wenbin Ying

IPC: C12N15/113

CPC classification number: A61B5/0071 ,  A61K31/713 ,  A61K49/0021 ,  C07D311/30 ,  C07F9/6533 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compositions and methods for preventing or treating a malignant tumor in a mammal in need thereof, by administering to the mammal a therapeutically effective amount of a composition comprising RNAi molecules, which RNAi molecules can be active in reducing expression of Hsp47, or a combination of RNAi molecules active for Hsp47 and p21.

Abstract translation: 本发明提供了通过向哺乳动物施用治疗有效量的包含RNAi分子的组合物来预防或治疗有需要的哺乳动物的恶性肿瘤的组合物和方法，该RNAi分子可以有效地降低Hsp47的表达，或 用于Hsp47和p21的RNAi分子的组合。

公开(公告)号：US20160208256A1

公开(公告)日：2016-07-21

申请号：US14979571

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Jens Harborth ,  Cima Cina ,  Kwok Yin Tsang ,  Wenbin Ying ,  Hirokazu Takahashi

IPC: C12N15/113

CPC classification number: C07F9/6533 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human p21 using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

Abstract translation: 本发明提供了使用RNA干扰来调节人p21的表达的化合物，组合物和方法。 RNA干扰分子可用于预防或治疗恶性肿瘤等疾病的方法。 提供一系列siRNA结构，其具有一个或多个核苷酸被修饰或化学修饰。 有利的结构包括位于种子区域中具有2'-脱氧核苷酸的siRNA以及其它核苷酸修饰。

公开(公告)号：US20160208254A1

公开(公告)日：2016-07-21

申请号：US14979567

申请日：2015-12-28

Applicant: Nitto Denko Corporation

Inventor： Yoshiro Niitsu ,  Kenjirou Minomi ,  Hirokazu Takahashi ,  Erika Terada ,  Jens Harborth ,  Cima Cina ,  Jun Zhang ,  Mohammad Ahmadian ,  Wenbin Ying

IPC: C12N15/113

CPC classification number: C07F9/6533 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/322 ,  C12N2310/344 ,  C12N2310/3515 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2320/35 ,  C12N2320/53 ,  C12Q1/02 ,  G01N33/582 ,  H05K999/99 ,  C12N2310/3533 ,  C12N2310/3531 ,  C12N2310/321 ,  C12N2310/3521

Abstract: This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. A nucleic acid molecule can have a) a polynucleotide sense strand and a polynucleotide antisense strand; b) each strand of the molecule being from 15 to 30 nucleotides in length; c) a contiguous region of from 15 to 30 nucleotides of the antisense strand being complementary to a sequence of an mRNA encoding GST-π; and d) at least a portion of the sense strand can be complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length.

Abstract translation: 本发明提供了用于调节人GST-＆pgr的表达的化合物，组合物和方法。 使用RNA干扰。 RNA干扰分子可用于预防或治疗恶性肿瘤等疾病的方法。 核酸分子可具有a）多核苷酸有义链和多核苷酸反义链; b）分子的每条链长度为15至30个核苷酸; c）反义链的15至30个核苷酸的连续区域与编码GST-的mRNA的序列互补; 和d）所述有义链的至少一部分可以与所述反义链的至少一部分互补，并且所述分子具有长度为15至30个核苷酸的双链体区。

公开(公告)号：US09308267B2

公开(公告)日：2016-04-12

申请号：US13913918

申请日：2013-06-10

Applicant: Nitto Denko Corporation

Inventor： Joseph E. Payne ,  John A. Gaudette ,  Zheng Hou ,  Mohammad Ahmadian ,  Lei Yu ,  Victor Knopov ,  Violetta Akopian ,  Priya Karmali ,  Richard P. Witte ,  Neda Safarzadeh ,  Wenbin Ying ,  Jun Zhang

IPC: A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  C07C271/16 ,  C07D333/40 ,  C07C317/44 ,  C07C333/04 ,  C07C235/08 ,  C07C237/08 ,  C07D207/16 ,  A61K47/14 ,  A61K9/127 ,  C07D333/38 ,  C07C323/60

CPC classification number: A61K47/20 ,  A61K9/1272 ,  A61K47/14 ,  A61K47/18 ,  A61K47/22 ,  C07C235/08 ,  C07C237/08 ,  C07C237/16 ,  C07C271/16 ,  C07C317/44 ,  C07C323/60 ,  C07C333/04 ,  C07D207/16 ,  C07D333/38 ,  C07D333/40 ,  Y10T428/2998

Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Abstract translation: 该描述针对可用于增强脂质体中治疗剂递送的可离子化脂质。

公开(公告)号：US11926831B2

公开(公告)日：2024-03-12

申请号：US17661803

申请日：2022-05-03

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Jens Harborth ,  Cima Cina ,  Wenbin Ying ,  Jane Zheng ,  Narendra Vaish

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12Y205/01018 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/343 ,  C12N2310/321 ,  C12N2310/3521 ,  C12N2310/322 ,  C12N2310/3533

Abstract: This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

公开(公告)号：US20220267779A1

公开(公告)日：2022-08-25

申请号：US17661803

申请日：2022-05-03

Applicant: Nitto Denko Corporation

Inventor： Kenjirou Minomi ,  Jens Harborth ,  Cima Cina ,  Wenbin Ying ,  Jane Zheng ,  Narendra Vaish

IPC: C12N15/113

Abstract: This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

公开(公告)号：US11364200B2

公开(公告)日：2022-06-21

申请号：US16182571

申请日：2018-11-06

Applicant: Nitto Denko Corporation

Inventor： Kwok Yin Tsang ,  Bharat Majeti ,  John Gaudette ,  Roger Adami ,  Hao Bai ,  Wenbin Ying

IPC: A61K9/127 ,  A61K47/10 ,  A61K47/69 ,  A61K31/7105 ,  A61K47/14 ,  C07C201/00 ,  B82Y5/00

Abstract: This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.

公开(公告)号：US11318099B2

公开(公告)日：2022-05-03

申请号：US16182571

申请日：2018-11-06

Applicant: Nitto Denko Corporation

Inventor： Kwok Yin Tsang ,  Bharat Majeti ,  John Gaudette ,  Roger Adami ,  Hao Bai ,  Wenbin Ying

IPC: A61K9/127 ,  A61K47/10 ,  A61K47/69 ,  A61K31/7105 ,  A61K47/14 ,  C07C201/00 ,  B82Y5/00

Abstract: This invention includes fusogenic compounds, and compositions and methods of use thereof. The fusogenic compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to incorporate or encapsulate active agents, to deliver and distribute the active agents to cells, tissues, organs, and subjects.